Business
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State.
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"IRVING, Texas, May 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State.","length":502,"tagName":"p"},{"type":"image","alt":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","displaySize":"","headline":null,"caption":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":359,"url":"https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DYkfDi5YhqiUCC4hCHfZpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYzMw--/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/xS87Ss8EcVJzBN8xSSK9jA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTU3NA--/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359}},"href":"https://mma.prnewswire.com/media/830740/Caris_Life_Sciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Caris Assure is a blood‑based molecular profiling test designed to support comprehensive biomarker analysis using a minimally invasive blood sample. Caris Assure uses circulating nucleic acids sequencing (cNAS) to analyze the whole exome (DNA) and whole transcriptome (RNA) of 22,000 genes. This comprehensive test identifies tumor alterations, clonal hematopoiesis (CH) and inherited variants, pharmacogenomic alterations, microsatellite instability (MSI) and tumor mutational burden (TMB).","length":496,"tagName":"p"},{"type":"text","content":"The submission initiates the formal review process required by New York State for clinical laboratories seeking to perform testing on specimens collected from New York patients. Through the Wadsworth Center, CLEP conducts comprehensive reviews of laboratory permits and laboratory-developed tests to evaluate analytical validation, quality sys...